SBC MEDICAL GROUP HOLDINGS INCRPRTD C/WTS 17/09/2029 (TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 43.36 M

Revenue: As of FY2025 Q2, the actual value is USD 43.36 M.

EPS: As of FY2025 Q2, the actual value is USD 0.02.

EBIT: As of FY2025 Q2, the actual value is USD 13.54 M.

Segment Revenue

• Franchising Revenue: $10,007,581 for Q2 2025, a decrease of 31.58% from $14,626,256 in Q2 2024.
• Procurement Revenue: $15,756,519 for Q2 2025, an increase of 16.40% from $13,536,608 in Q2 2024.
• Management Services Revenue: $5,138,578 for Q2 2025, a decrease of 69.24% from $16,705,597 in Q2 2024.
• Rental Services Revenue: $6,851,176 for Q2 2025, an increase of 98.40% from $3,453,173 in Q2 2024.
• Other Revenues: $5,604,993 for Q2 2025, an increase of 17.25% from $4,780,446 in Q2 2024.

Operational Metrics

• Net Income: $2,439,852 for Q2 2025, a decrease of 86.85% from $18,557,325 in Q2 2024.
• Gross Profit: $30,010,577 for Q2 2025, a decrease of 23.87% from $39,419,675 in Q2 2024.
• Operating Expenses: $15,456,385 for Q2 2025, an increase of 27.43% from $12,129,115 in Q2 2024.
• Income from Operations: $14,554,192 for Q2 2025, a decrease of 46.67% from $27,290,560 in Q2 2024.
• Income Tax Expense: $11,100,509 for Q2 2025, an increase of 30.15% from $8,529,110 in Q2 2024.

Cash Flow

• Net Cash Used in Operating Activities: -$6,411,168 for the six months ended June 30, 2025, compared to $22,874,760 provided by operating activities for the same period in 2024.
• Net Cash Provided by Investing Activities: $15,397,998 for the six months ended June 30, 2025, compared to -$9,405,716 used in investing activities for the same period in 2024.
• Net Cash Provided by Financing Activities: $6,901,719 for the six months ended June 30, 2025, compared to -$109,341 used in financing activities for the same period in 2024.

Unique Metrics

• Change in Fair Value of Cryptocurrencies: $111,632 for Q2 2025, compared to nil for Q2 2024.
• Gain on Redemption of Life Insurance Policies: $8,746,138 for the six months ended June 30, 2025.

Future Outlook and Strategy

• Core Business Focus: The company plans to maintain and strengthen its market position and brand in the cosmetic medical treatment management market in Japan, Vietnam, and Singapore, and grow its presence globally.
• Non-Core Business: The company completed the disposal of its subsidiaries, Kijimadairakanko Inc. and Skynet Academy Co., Ltd., in December 2024.
• Priority: The company expects to deploy capital for investment opportunities that align with its growth strategy, selectively pursuing prospects in the expanding global medical aesthetics market.